Related Experiment Video

Updated: Mar 8, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

17.2K

Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children

Lucia Schena, Cristina Meazza, Sara Pagani

    Journal of Pediatric Endocrinology & Metabolism : JPEM
    |January 19, 2017
    PubMed

    Insights

    Short children without growth hormone deficiency (GHD) may benefit from growth hormone (GH) treatment, showing similar growth outcomes to GHD patients. Careful patient selection is recommended for cost-effectiveness.

    Area of Science:

    • Pediatric Endocrinology
    • Growth Hormone Therapy
    • Childhood Growth Disorders

    Background:

    • Varied responses to growth hormone (GH) treatment in idiopathic short stature children are noted.
    • Investigating the efficacy of long-term GH treatment in non-growth hormone-deficient (non-GHD) short children is crucial.

    Purpose of the Study:

    • To compare the benefits of long-term GH treatment in non-GHD short children versus GHD patients.
    • To assess growth outcomes and insulin-like growth factor 1 (IGF-I) levels in both groups.

    Main Methods:

    • Enrolled 22 prepubertal non-GHD children and 22 age/sex-matched GHD patients.
    • Ensured comparable height, BMI, bone age, and baseline IGF-I levels between groups.
    • Administered recombinant human GH (rhGH) and monitored patients until adult height attainment.

    Main Results:

    • Both groups exhibited parallel growth and achieved similar final height-standard deviation scores (SDS) and height gains.
    • Non-GHD patients showed significantly lower IGF-I serum concentrations post-therapy compared to GHD patients (p=0.0055).

    Conclusions:

    • GH treatment demonstrated similar efficacy in promoting growth for both short non-GHD and GHD children.
    • Careful selection of non-GHD children for GH therapy is advised to optimize treatment justification and cost-effectiveness.
    Abstract

    More Related Videos

    Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations05:04

    Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

    Published on: February 2, 2024

    1.0K
    Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection02:22

    Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection

    Published on: April 12, 2024

    1.1K

    Related Concept Videos

    Nature and Nurture01:10

    Nature and Nurture

    Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
    22.6K
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    1.0K
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    304
    Hormones and Bone Tissue01:17

    Hormones and Bone Tissue

    The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
    Hormones That Influence Osteoblasts and/or Maintain the Matrix
    Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
    4.1K
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    343